Cardiovascular Research Laboratory, Cardiac Thoracic Vascular Department -University of Pisa, Pisa, Italy.
Curr Pharm Des. 2011;17(28):2973-86. doi: 10.2174/138161211798157667.
Hypertension is a complex, multifactorial disease; genetic factors represent one third to half of the inter-individual variability of blood pressure values. Among the causes of secondary hypertension are a group of disorders with a Mendelian inheritance pattern. Recent advances in molecular biology have revealed the pathogenesis of hypertension in many of these conditions. Remarkably, the mechanism in every case has proved to be upregulation of sodium Na reabsorption in the distal nephron, with accompanying expansion of extracellular volume. On the contrary in the essential hypertension the underlying pathogenetic mechanism is more complex because of interplay between several 'risk' genes and environmental factors. It is assumed that blood pressure is under the control of a large number of genes each of which has only relatively mild effects. It has therefore been difficult to discover the genes that contribute to blood pressure variation using traditional approaches including candidate gene studies and linkage studies. Recent development of genotyping technology made large scale genome-wide association studies possible. This approach and the study of monogenic forms of hypertension has led to the discovery of novel and robust candidate genes for human essential hypertension, many of which require functional analysis in experimental models. This review summarizes the current findings for candidate genes associated with blood pressure and focuses on recent advances and future potential of pharmacogenetics of hypertension, with the intent to clarify what amount of these investments in basic science research will be delivered into benefits to patients.
高血压是一种复杂的、多因素的疾病;遗传因素代表血压值个体间差异的三分之一到一半。继发性高血压的病因中有一组具有孟德尔遗传模式的疾病。分子生物学的最新进展揭示了许多此类疾病的高血压发病机制。值得注意的是,每种情况下的机制都被证明是远端肾单位钠离子 Na 重吸收的上调,伴随细胞外体积的扩张。相反,在原发性高血压中,由于几个“风险”基因和环境因素的相互作用,潜在的发病机制更为复杂。人们认为血压受许多基因的控制,每个基因的影响都相对较小。因此,使用传统方法(包括候选基因研究和连锁研究)发现导致血压变化的基因一直很困难。基因分型技术的最新发展使得大规模全基因组关联研究成为可能。这种方法和单基因形式的高血压研究导致了新的和稳健的原发性高血压候选基因的发现,其中许多基因需要在实验模型中进行功能分析。这篇综述总结了与血压相关的候选基因的最新发现,并重点介绍了高血压药物遗传学的最新进展和未来潜力,旨在阐明这些基础科学研究的投资中有多少将为患者带来益处。